Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $17.66B |
| Gross Profit (TTM) | $8.12B |
| EBITDA | $2.42B |
| Operating Margin | 14.00% |
| Return on Equity | 10.20% |
| Return on Assets | 4.07% |
| Revenue/Share (TTM) | $18.55 |
| Book Value | $13.53 |
| Price-to-Book | 2.02 |
| Price-to-Sales (TTM) | 1.51 |
| EV/Revenue | 1.631 |
| EV/EBITDA | 9.57 |
| Quarterly Earnings Growth (YoY) | 61.40% |
| Quarterly Revenue Growth (YoY) | 0.50% |
| Shares Outstanding | $977.43M |
| Float | $976.62M |
| % Insiders | 0.00% |
| % Institutions | 5.41% |
Volatility is currently contracting
Philips' largest shareholder Exor , the investment arm of Italy's Agnelli family, has extended its agreement with the health technology firm, giving it the flexibility to increase its stake to up to 22%, the companies said on Tuesday.
August 6, 2026 New collaborations expand wearable and out-of-hospital monitoring capabilities, helping support continuous patient visibility from admission through recovery at home Amsterdam, Netherlands. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare, further expanding its open monitoring ecosystem.
The "Share the Care Connector" helps turn good intentions into real, meaningful support and connection for new moms during the postpartum period, when they need it most. CAMBRIDGE, Mass.
PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.
Koninklijke Philips N.V. (PHG) Q2 2026 Earnings Call Transcript
Shares in Philips fell as much as 11% in early European morning trade, wiping out the stock's gains since the start of the year.
Koninklijke Philips NYSE: PHG reported 4.1% comparable sales growth in the second quarter of 2026, supported by growth across all segments, while maintaining its full-year underlying sales and profitability outlook amid higher tariffs, cost inflation and continued weakness in China's health systems market.
The Dutch health-technology company said customer demand for its products remains healthy, with large orders in North America shifting into the third quarter, while Europe delivered strong double-digit growth.
July 27, 2026 Q2 2026 Group performance Comparable order intake declined 1%, due to timing of certain large orders Group sales of EUR 4.4 billion, reflecting 4% comparable sales growth Income from operations of EUR 609 million, including US tariff refund benefit of EUR 186 million Adjusted EBITA margin increased to 16.4%, including US tariff refund benefit of effectively 4.2% Operating cash flow of EUR 376 million, with free cash flow of EUR 222 million including receipt of US tariff refund 2026 comparable sales growth outlook reiterated; Adjusted EBITA and free cash flow outlook updated to reflect US tariff refund Roy Jakobs, CEO of Royal Philips: “We delivered another solid quarter with comparable sales growth of 4%, driven by all business segments, and strong disciplined execution within an uncertain macro environment. Customer demand for our innovations remains healthy, with certain large orders in North America shifting into the third quarter, while Europe delivered strong double-digit order growth.
July 21, 2026 New sensor advances pulse oximetry reliability for diverse patient populations through innovation and rigorous validation. Cambridge, MASS – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced FDA 510(k) clearance of its next-generation reusable Philips SpO₂ clip sensor, reinforcing the company's ongoing commitment to providing clinicians with trusted oxygen saturation measurements that support confident care for every patient.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PHG and any ticker you trade — then tracks every position and per-strategy win rate.
